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Abstract: 
Introduction: The incidence of spinal cord injury (SCI) caused by many events, including traffic accidents, mining 
and construction accidents, seismic and natural disasters, has tended to rise year on year. The pathology of SCI 
usually includes primary injury and secondary injury.  
Aims and objectives: The basic aim of the study is to analyze the comparison of effects of methotrexate with the 
combination of methylprednisolone in spinal cord injury.  
Material and methods: This cross sectional study was conducted in Fatima Memorial Hospital Lahore during 
March 2018 to November 2018. A total of 100 patients who were suffering from spinal injury due to any reason 
were included in this study. After analysis dose of drug according to schedule was given to the all patients.  For 
biochemical analysis 5cc blood sample was taken from vein and sample were processed with phosphate buffer 
saline using homogenizer. Thiobarbituric acid reactive substances were measured according to the method of 
Mihara et al. Myeloperoxidation (MPO) activity of the tissue sample was measured according to the method of 
Suzuki et al.  
Results: The variations between the mean values of MPO levels were significant according to the ANOVA and t-test. 
There were significant difference between control groups and treated groups. The data shows that the group of 
patients which was treated with both MTX and MP as a combine effect shows more close values to the control. But 
the separate effect shows somehow different values as compared to control 
Corresponding author:  
Dr. Nabila Javed 
Basic Health Unit Jallo Chak, Jhelum 
E-mail:- nabilajaved378@gmail.com 
 
 
 
Please cite this article in press Nabila Javed et al., Analysis Of Comparison Of Effects Of Methotrexate With The 
Combination Of Methylprednisolone In Spinal Cord Injury., Indo Am. J. P. Sci, 2019; 06(03). 
QR code 
 
 
IAJPS 2019, 06 (03), 1-7                               Nabila Javed et al                         ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 5538 
INTRODUCTION: 
The incidence of spinal cord injury (SCI) caused by 
many events, including traffic accidents, mining and 
construction accidents, seismic and natural disasters, 
has tended to rise year on year. The pathology of SCI 
usually includes primary injury and secondary injury.  
Microglial cells produced superoxide and nitric oxide 
when they expose to oxidative stress. But according 
to modern treatment if we reduces the production of 
these cytokines by blocking these inflammatory cells, 
it will reduces the secondary cord damage (1). 
Primary injury often occurs in the spine, leading to 
SCI. The secondary damage includes inflammation, 
oxidative stress, neuronal apoptosis, intracellular and 
extracellular ion imbalance and a series of 
pathological reaction. Therefore, to avoid second 
injury and to promote the survival of axons and 
neurons, therapies aim to reduce or eliminate the 
destructive pathological response and to promote the 
regeneration, repair and functional reconstruction of 
nerve tissue in the chronic phase (2). 
Now a days low dose methotrexate (MTX) and 
methylprednisolone (MP) has been used for the 
treatment of some inflammatory diseases such as 
secondary spinal cord damage (3). Low dose MTX 
inhibits the proliferation of lymphocytes in any 
inflammatory response and also decreases the ability 
of leukocytes. Exact mechanism of this drug is still 
unknown but according to some studies it increases 
the adenosine accumulation at the inflammatory sites. 
Adenosine interacts with the receptors and decreases 
the inflammatory cells (4). 
MP is the first drug which is used for the treatment of 
spinal cord injury in animals and humans. This drug 
is considered to be the standard treatment method 
from whom which any other drugs will compare (5).  
High dose of MP inhibits the lipid peroxidation (6). 
Current studies investigated that lipid peroxidation is 
a major provider to the progressive damage of tissue 
injury. MP protects the membrane against lipid 
peroxidation and it must be remembered that MP is a 
glucocorticosteroid drug and it also act through 
another mechanism in addition to lipid peroxidation 
(7). 
Aims and objectives 
The basic aim of the study is to analyze the 
comparison of effects of methotrexate with the 
combination of methylprednisolone in spinal cord 
injury. 
 
MATERIAL AND METHODS 
This cross sectional study was conducted in Fatima 
Memorial Hospital Lahore during March 2018 to 
November 2018. A total of 100 patients who were 
suffering from spinal injury due to any reason were 
included in this study. The study was divided into 
following groups: 
Group A: Control group 
Group B: MTX- group  
Group C: MP- group  
Group D: MTX + MP 
After analysis dose of drug according to schedule 
was given to the all patients.  For biochemical 
analysis 5cc blood sample was taken from vein and 
sample were processed with phosphate buffer saline 
using homogenizer. Thiobarbituric acid reactive 
substances were measured according to the method of 
Mihara et al. Myeloperoxidation (MPO) activity of 
the tissue sample was measured according to the 
method of Suzuki et al. Blood was centrifuged at 
3000rpm for 10 minutes and after that pallet was 
resuspended. Remove the pallet and again centrifuge 
at 3000rpm for 5 minutes. The resultant supernatant 
was separated and used for the measurement of MPO 
activity. Add 50mM phosphate buffer, 0.5% 
hexadecyltrimethyl ammonium bromide (HETAB), 
1.6mM tetramethylbenzidine (TMB) and 2mM H2O2 
and make the final volume of 1 ml. The reaction was 
started by the addition of H2O2 and absorbance was 
measured at 650 nm. 
 
Statistical analysis 
Statistical analysis (one way-Anova Test and Post 
Hoc) was performed using the SPSS software 
program (18.0). All results were expressed as the 
mean ± standard deviation (SD). As P value <0.08 
was considered to be statistically signiﬁcant (14). 
 
RESULTS: 
The variations between the mean values of MPO 
levels were significant according to the ANOVA and 
t-test. There were significant difference between 
control groups and treated groups. The data shows 
that the group of patients which was treated with both 
MTX and MP as a combine effect shows more close 
values to the control. But the separate effect shows 
somehow different values as compared to control 
(Table 1). The graph also illustrate that there is a 
significant relationship between control and treated 
groups. The p- values presented in the table 2 shows 
the clear significant relationship in the evaluation of 
LPO (table 2). 
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Table 1: Values of mean MPO and LPO in all groups 
Groups Variabl
es 
Maximum Minimum Mean±SD 
Control LPO 35.33 30.35 30.00±7.32 
MPO 0.01 0.00 0.00±1.57 
MTX LPO 58.63 54.30 54.30±7.46 
MPO 14.53 11.36 12.50±0.84 
MP LPO 44.14 40.00 42.00±9.22 
MPO 5.32 4.85 3.25±5.20 
MTX (High dose)+MP LPO 35.00 33.00 32.25±11.68 
MPO 64.14 60.14 62.14±6.14 
MTX+MP ( High dose) LPO 14.80 13.80 12.32±2.61 
MPO 38.00 36.33 35.32±0.64 
Table 2: Post-Hoc test values for all groups 
No. Of observations Study groups df P-value 
1 Control 3 0.018* 
2 MTX  
 
1 0.019* 
3 MP  
 
1 0.017* 
4 MTX (High dose)+MP 2 0.500 
5 MTX+MP ( High dose) 1 0.222 
*p≤ 0.05 as significant value, df= degree of freedom 
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Figure 01: activity of MPO in all groups 
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DISCUSSION: 
Our results indicated that the dose of 30mg/kg body 
weight of MTX and MD shows a significant effect 
but as compared to this combine treatment show 
synergistic effect. Due to this synergistic effect 
recovery is more close to the control group. MD has 
no effect on overall weight and any other level but 
MTX shows some notable effects (7). The 
inflammatory response in SCI is biphasic. In first 
phase lysosomal degradation and formation of free 
radicals occurred and in the next phase tissues 
damaged (8). 
There are many pharmacological agents which 
described or considered as a potentially strong 
therapeutic effects for SCI. Steroids are also accepted 
as a best possible option for the treatment of SCI. 
They have antioxidant and anti-inflammatory and 
may be favorable in a time- and dose-dependent 
manner (9). They have also anti-edema activities. 
Methylprednisolone (MP) acts through a variety of 
mechanisms to prevent the occurrence of secondary 
SCI and is currently the only food and drug 
administration-approved drug for the treatment of 
acute SCI. However, high doses of MP lead to many 
side effects, including glucocorticoid-induced 
infection, diabetic complications, and impaired 
wound healing, and can endanger the lives of 
patients. Therefore, many experts suggest that high-
dose MP shock therapy should not be used as a 
conventional treatment, although it can be used as a 
selective treatment strategy (10). 
Methotrexate (MTX) is a common anti-rheumatic 
drug that can improve the disease state and has anti-
inflammatory and immunosuppressive effects. MTX 
is generally used to compensate for the poor efficacy 
of glucocorticoid or other anti-rheumatic drugs. MTX 
can also be combined with hormones in early 
rheumatoid arthritis, so as to reduce hormone doses, 
thereby alleviating hormone side effects. MTX can 
be taken long-term because of low cost, various 
routes of administration, steady long-term efficacy 
and high safety; namely, it can be taken as an anchor 
drug (11). 
CONCLUSION: 
It is concluded that low dose methotrexate is more 
effective as compared to methylprednisolone in 
secondary spinal cord injury in patients. 
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